A randomized controlled trial of velanfaxine and paroxetine in patients with depression

AIM:To compare the efficacy and safety of velanfaxine extended release and paroxetine in the treatment of depression.METHODS:Eighty inpatients with a diagnosis of depression were randomly assigned to velanfaxine or paroxetine groups for 8 weeks treatment.Efficacy and safety were assessed by HAMD (Hamilton Rating Scale for depression),CGI (Clinical Impression rating scale) and TESS.Assessments were performed at baseline and at the end of wk 1,2,4 and 8 of the trial.RESULTS:There was significant difference between velanfaxine and paroxetine groups at the end of wk 1 (P0.05).Decrease in HAMD scores were 14±s 4 and 14±4 from baseline in velanfaxine and paroxetine groups,respectively.Both groups showed a significant improvement after 8 weeks treatment (P0.01).There was no significant difference between the mean HAMD scores of two groups (P0.05) The rates of adverse reactions were 20% and 20% in velanfaxine and paroxetine groups,respectively.The adverse reactions of both were less (P0.05). CONCLUSION:Velanfaxine is as effective and safe as paroxetine in the treatment of depression.Velanfaxine has rapid efficacy.Both two drugs have good safety and compliance in patients with depression.